Antibody-mediated cell depletion therapies in multiple sclerosis

Development of disease-modifying therapies including monoclonal antibody (mAb)-based therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over the past decades. Most of the mAb-based therapies approved for MS deplete immune cell subsets and act through activation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariottini, Alice, Muraro, Paolo A., Lünemann, Jan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511140/
https://www.ncbi.nlm.nih.gov/pubmed/36172350
http://dx.doi.org/10.3389/fimmu.2022.953649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511140/
https://www.ncbi.nlm.nih.gov/pubmed/36172350
http://dx.doi.org/10.3389/fimmu.2022.953649

Ejemplares similares